WAKEFIELD, Mass.--(BUSINESS WIRE)--Publishing in the current edition of PLOS ONE, scientists at Genetics Research LLC (“GR”), and the University of New Hampshire, have demonstrated the ability of GR’s CRISPR/Cas9-based technology, called Negative EnrichmentTM, to increase enrichment specificity, lower cost, and increase throughput for enriching sequence specific nucleic acids. These novel and valuable findings are based on the patented and patent-pending technology of GR, an inventor of innovative technologies for the development of products for genomic analysis in research, diagnostics, and companion diagnostics.
The novel method for enriching sequence specific nucleic acids, in which Cas endonuclease complexes are used to protect targeted sequences of interest in the presence of exonucleases, does not require specific targeting of background DNA. The exonucleases degrade substantially all of the nucleic acid in a sample except for the nucleic acid of interest, thereby leaving the nucleic acid of interest isolated and amenable to analysis. Furthermore, the platform is agnostic on the size of the targeted sequence. The paper also illustrates how Negative EnrichmentTM is suitable for multi-plexing, because the Cas9/sgRNA complex does not have sequence-specific bias of hybridization-based approaches.
Tony Shuber, President and COO of Genetics Research, said, “Because our Negative EnrichmentTM platform does not rely on in vitro replication or hybridization associated enrichment, the approach can be coupled with a variety of analytical approaches including non-amplification associated single molecule platforms and POC devices. In addition, we have observed the ability to perform negative enrichment directly in plasma.”
Thomas A. Shields, Chairman, CEO and a principal investor in Genetics Research, said, “the potential for a substantial, positive impact on research and clinical work from this next generation of target enrichment technologies we have developed at Genetics Research is very encouraging.”
About Genetics Research LLC
Genetics Research is an inventor of innovative, proprietary technologies for the development of products supporting genomic analysis in research, diagnostics, and therapeutics. Genetics Research has developed Negative EnrichmentTM, a new, low cost and simple sequence specific enrichment technology platform. This unique CRISPR/Cas9 approach can enrich for long DNA fragments out of a complex background, and demonstrates significant economic value for NGS analysis.
More information is available at www.gen-res.com.